Dermira, Inc. (NASDAQ:DERM) Files An 8-K Submission of Matters to a Vote of Security Holders

13

Dermira, Inc. (NASDAQ:DERM) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07Submission of Matters to a Vote of Security Holders.

On June 13, 2017, Dermira, Inc. (the Company) held its 2017
annual meeting of stockholders (the Annual Meeting).Proxies for
the Annual Meeting were solicited to Regulation 14A of the
Securities Exchange Act of 1934, as amended (the Exchange Act).
Of the 41,518,648 shares of the Companys common stock outstanding
as of the record date of April 19, 2017, 34,893,895 shares were
represented at the Annual Meeting, either in person or by proxy,
constituting approximately 84% of the outstanding shares of
common stock. The matters voted on at the Annual Meeting and the
votes cast with respect to each such matter are set forth below:

1.

Election of Class III Directors.The following nominees
were re-elected to serve as Class III directors, each to
serve a three-year term expiring at the Companys 2020
annual meeting of stockholders and until his successor
has been duly elected and qualified or his earlier
resignation or removal, based on the following results of
voting:

Nominee

Votes For

Votes Withheld

Broker Non-Votes

Mark D. McDade

28,144,453

5,638,888

1,110,554

Jake R. Nunn

28,059,052

5,724,289

1,110,554

Thomas G. Wiggans

28,663,694

5,119,647

1,110,554

2.

Executive Compensation. On a non-binding advisory basis,
compensation paid to the Companys named executive
officers for the year ended December 31, 2016 was
approved, based on the following results of voting:

Votes For

Votes Against

Abstentions

Broker Non-Votes

33,489,468

258,352

35,521

1,110,554

3.

Frequency of Future Votes on Executive Compensation. On a
non-binding advisory basis, the option of once every year
was determined to be the preferred frequency with which
the Company is to hold an advisory stockholder vote to
approve executive compensation on a non-binding advisory
basis, based on the following results of voting:

One Year

Two Years

Three Years

Abstentions

31,000,395

102,270

2,680,676

4.

Ratification of Appointment of Independent Registered
Public Accounting Firm. The appointment of Ernst Young
LLP as the Companys independent registered public
accounting firm for the year ending December 31, 2017 was
ratified, based on the following results of voting:

Votes For

Votes Against

Abstentions

34,881,958

5,344

6,593

Based on therecommendation of the Companys Board of Directors
(the Board) for the Annual Meeting and the voting results with
respect to Proposal Number 3, the Board determined that
non-binding advisory votes on executive compensation will be
submitted for consideration by the Companys stockholders every
year until the next stockholder vote on frequency of stockholder
votes on the compensation of executives as required by Section
14A(a)(2) of the Exchange Act.


About Dermira, Inc. (NASDAQ:DERM)

Dermira, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor, that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn’s disease. DRM04 is a topical, small-molecule anticholinergic product for the treatment of hyperhidrosis. DRM01 is a topical, small-molecule sebum inhibitor for the treatment of acne.

An ad to help with our costs